The FDA cleared Corcept Therapeutics’ oral relacorilant (Lifyorli) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer—an approval arriving nearly four months ahead of schedule. The agency also granted accelerated approval to Denali Therapeutics’ tividenofusp alfa (Avlayah) for Hunter syndrome.